论文部分内容阅读
目的:观察胸腺肽在宫颈癌术后同步放化疗中的辅助疗效。方法:40例宫颈癌术后患者随机分成两组:观察组20例,应用胸腺肽辅助同步放化疗,胸腺肽每日静脉滴点20mg,每日一次,连用4周。对照组20例,同步放化疗。两组放化疗方案相同。评价治疗前后骨髓抑制情况,肝功能情况,患者KPS评分(即行为状态评分,Kamofsky PerformanceStatus)。结果:观察组骨髓抑制在治疗前后变化明显,肝功能变化不明显,患者KPS治疗后较治疗前提高,统计学有差异(P<0.05)。结论:胸腺肽在宫颈癌术后放化疗同步治疗中具有调节和增强人体细胞免疫功能的作用,患者骨髓抑制减轻,生活质量提高。
Objective: To observe the adjuvant effect of thymosin in concurrent chemoradiotherapy after cervical cancer. Methods: Forty patients with cervical cancer were randomly divided into two groups: observation group (n = 20), thymosin-assisted concurrent chemoradiation and thymosin daily intravenous drip point (20mg) once daily for 4 weeks. Control group of 20 patients, concurrent chemoradiation. The two groups of chemotherapy the same program. Evaluation of myelosuppression before and after treatment, liver function, patient KPS score (ie, performance status score, Kamofsky PerformanceStatus). Results: Myelosuppression in the observation group changed significantly before and after treatment, but the change of liver function was not obvious. The KPS in the observation group was significantly higher than that before treatment (P <0.05). Conclusion: Thymosin plays an important role in the regulation and enhancement of cellular immune function in patients with cervical cancer after radiotherapy and chemotherapy. The bone marrow suppression and quality of life of the patients are improved.